Events

Dr Christian Toouli, CEO and Managing Director of FivepHusion, said, "The ethics approval of the Phase II DART protocol is an exciting milestone towards our goal of evaluating Deflexifol as a promising therapy for these patients."

AusBiotech has announced that Australia's Biggest Week in Biotech 2027 will be held in Brisbane from 23–27 August, marking a shift from its traditional October timing.

Atmo Biosciences has been named a winner in Fast Company’s 2026 World Changing Ideas Awards, an annual program that recognises innovations delivering measurable impact across industries.

Dr Chris Baldwin, CEO and Managing Director, said, “Receipt of ethics approval for our KappaMab Phase 2b clinical trial in combination with pomalidomide and dexamethasone is a significant milestone for HaemaLogiX."

Neurizon Therapeutics has executed a long-term supply agreement with Elanco Animal Health that gives the company access to scalable Good Manufacturing Practice supply of monepantel, the active pharmaceutical ingredient in its lead asset NUZ‑001.

Percheron Therapeutics has announced the successful completion of manufacturing for a new batch of HMBD-002 drug substance ahead of planned clinical trials.

Racura Oncology has secured $34.3 million following a series of fundraising initiatives supported by new and existing shareholders, giving the company a strong cash balance to fully fund its RC220 clinical programs in Acute Myeloid Leukaemia, EGFRm non-small cell lung cancer and anthracycline cardioprotection in solid tumour patients.

Nyrada says its PROTECT MI Phase 2a study of Xolatryp remains on track for completion in calendar 2027 and is moving through the staged rollout typical of first-in-patient cardiovascular studies.

Memphasys has announced a 12-month exclusive national supply agreement with Monash IVF Group for the Felix automated sperm selection system.

Melbourne-based Dimerix has granted Everest Medicines exclusive rights to commercialise DMX 200 for all indications, including Focal Segmental Glomerulosclerosis, in China, South Korea, and parts of Southeast Asia.

Entropy CEO Jason Carroll said, “The DSMB’s recommendation to progress to Cohort 2 without any protocol changes is an important milestone for the TRP-8803 program and provides independent validation of the favourable safety profile observed in Cohort 1.”

Paradigm Biopharmaceuticals has announced the completion of enrolment in its pivotal Phase 3 trial of Zilosul injectable pentosan polysulfate sodium for knee osteoarthritis, a milestone that moves the company into the next phase of clinical and corporate catalysts.